Tags

Type your tag names separated by a space and hit enter

Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000).
Chemotherapy. 2004 Jun; 50(3):143-51.C

Abstract

BACKGROUND

The Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) longitudinal global surveillance study examines the antibacterial susceptibility of community-acquired respiratory pathogens.

METHODS AND RESULTS

Data from isolates collected in Germany in 1999-2000 in the PROTEKT study show that 8.3% of pneumococcal isolates (n = 325) had reduced susceptibility to penicillin and 2.2% were fully resistant. Erythromycin resistance was 15.7% overall and particularly high in Leipzig (31.6%). All penicillin- and erythromycin-resistant strains were inhibited by telithromycin (MIC < or =0.5 mg/l) and linezolid (MIC < or =2 mg/l). Beta-lactamase was produced by 3.2% of Haemophilus influenzae (9/284) and 89.5% of Moraxella catarrhalis strains (111/124). All Streptococcus pyogenes isolates (n = 87) were susceptible to penicillin, although 9.2% were resistant to macrolides.

CONCLUSIONS

Penicillin resistance in Germany remains low; however, the prevalence of antimicrobial resistance among common respiratory pathogens is rising, particularly against macrolides. Continued surveillance is necessary to guide optimal empirical therapy, and new antimicrobials, like telithromycin, need to be developed with improved potency against target pathogens and low propensity for the development of resistance.

Authors+Show Affiliations

Reinert RR
National Reference Center for Streptococci, Institute of Medical Microbiology, University Hospital, Aachen, Germany. Reinert@rwth-aachen.de
Rodloff AC
No affiliation info available
Halle E
No affiliation info available
Baer W
No affiliation info available
Beyreiss B
No affiliation info available
Seifert H
No affiliation info available
Wichelhaus TA
No affiliation info available
Maass M
No affiliation info available
Mehl M
No affiliation info available

MeSH

Anti-Bacterial AgentsCommunity-Acquired InfectionsDrug Resistance, BacterialGermanyHaemophilus influenzaeHumansKetolidesLongitudinal StudiesMicrobial Sensitivity TestsMoraxella catarrhalisMulticenter Studies as TopicPenicillin ResistancePopulation SurveillanceRespiratory Tract InfectionsStreptococcus pneumoniaeStreptococcus pyogenes

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15272227

Citation

Reinert, R R., et al. "Antibacterial Resistance of Community-acquired Respiratory Tract Pathogens Recovered From Patients in Germany and Activity of the Ketolide Telithromycin: Results From the PROTEKT Surveillance Study (1999-2000)." Chemotherapy, vol. 50, no. 3, 2004, pp. 143-51.
Reinert RR, Rodloff AC, Halle E, et al. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000). Chemotherapy. 2004;50(3):143-51.
Reinert, R. R., Rodloff, A. C., Halle, E., Baer, W., Beyreiss, B., Seifert, H., Wichelhaus, T. A., Maass, M., & Mehl, M. (2004). Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000). Chemotherapy, 50(3), 143-51.
Reinert RR, et al. Antibacterial Resistance of Community-acquired Respiratory Tract Pathogens Recovered From Patients in Germany and Activity of the Ketolide Telithromycin: Results From the PROTEKT Surveillance Study (1999-2000). Chemotherapy. 2004;50(3):143-51. PubMed PMID: 15272227.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000). AU - Reinert,R R, AU - Rodloff,A C, AU - Halle,E, AU - Baer,W, AU - Beyreiss,B, AU - Seifert,H, AU - Wichelhaus,T A, AU - Maass,M, AU - Mehl,M, PY - 2003/03/14/received PY - 2003/10/27/accepted PY - 2004/7/24/pubmed PY - 2005/1/12/medline PY - 2004/7/24/entrez SP - 143 EP - 51 JF - Chemotherapy JO - Chemotherapy VL - 50 IS - 3 N2 - BACKGROUND: The Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) longitudinal global surveillance study examines the antibacterial susceptibility of community-acquired respiratory pathogens. METHODS AND RESULTS: Data from isolates collected in Germany in 1999-2000 in the PROTEKT study show that 8.3% of pneumococcal isolates (n = 325) had reduced susceptibility to penicillin and 2.2% were fully resistant. Erythromycin resistance was 15.7% overall and particularly high in Leipzig (31.6%). All penicillin- and erythromycin-resistant strains were inhibited by telithromycin (MIC < or =0.5 mg/l) and linezolid (MIC < or =2 mg/l). Beta-lactamase was produced by 3.2% of Haemophilus influenzae (9/284) and 89.5% of Moraxella catarrhalis strains (111/124). All Streptococcus pyogenes isolates (n = 87) were susceptible to penicillin, although 9.2% were resistant to macrolides. CONCLUSIONS: Penicillin resistance in Germany remains low; however, the prevalence of antimicrobial resistance among common respiratory pathogens is rising, particularly against macrolides. Continued surveillance is necessary to guide optimal empirical therapy, and new antimicrobials, like telithromycin, need to be developed with improved potency against target pathogens and low propensity for the development of resistance. SN - 0009-3157 UR - https://www.unboundmedicine.com/medline/citation/15272227/Antibacterial_resistance_of_community_acquired_respiratory_tract_pathogens_recovered_from_patients_in_Germany_and_activity_of_the_Ketolide_Telithromycin:_results_from_the_PROTEKT_surveillance_study__1999_2000__ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓3]

Related Citations

More